Oligo Modification By Application

Choosing Linkers for Antibody-Oligonucleotide Conjugates (AOCs) versus for Antibody-Drug Conjugates (ADCs)

September 18, 2025 / September 19, 2025 by Dawn Lam

Antibodies have unique targeting specificity for different cell- and tissue-types.  This has led to rapid growth in Antibody-Drug Conjugates (ADCs) for the treatment of cancer, which can deliver a cytotoxic payload to a particular cell-type or to cancerous cells that overexpress specific receptors.  Oligonucleotides, such as antisense oligos (ASOs) and small-interfering RNA oligos (siRNAs), have […]

Read more »